Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
144estimated
Sites
9
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-02 | actual | When the study began enrolling |
| Primary completion | 2025-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-01-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CLL/SLL
Intervention
- Drug: Lisaftoclax
Primary outcomes
what the primary-completion date above is the date OFPrimary Toxicity Endpoint: dose limiting toxicity (DLT)
measured 42 days
Maximally tolerated dose (MTD)
measured 42 days
Publications
- PMID 41109219 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed